OPM Biosciences 奥浦迈
27 significant filings since 29 May 2026: 7 on change of interest, 6 on equity incentive and 5 on major holder selling, and 4 other kinds. The latest, on 25 Sep 2026: 奥浦迈：关于持股5%以下特定股东减持股份计划公告. On 23 Jul 2026 the company said it expects net profit for the period ending 30 Jun 2026 to rise by 229.00% from the same period a year earlier.
自 29 May 2026 起有 27 份重大公告：change of interest 7 份、equity incentive 6 份、major holder selling 5 份，另有 4 类。最新一份（25 Sep 2026）：奥浦迈：关于持股5%以下特定股东减持股份计划公告。23 Jul 2026 公司预告截至 30 Jun 2026 的净利润较上年同期上升 229.00%。
The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 Every rated report on this company said Buy or Outperform.
No broker has changed its rating on this company in the reports held.
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 东吴证券 | 朱国广,刘若彤 | Buy 买入 | 7 May 2026 | 1 | — |
| 信达证券 | 唐爱金,章钟涛 | Unrated | 1 May 2026 | 1 | — |
| 国信证券 | 马千里,陈曦炳,彭思宇 | Outperform 增持 | 28 Apr 2026 | 1 | — |
| 开源证券 | 余汝意,石启正 | Buy 买入 | 26 Apr 2026 | 2 | — |
| 西南证券 | 杜向阳 | Unrated | 3 Nov 2025 | 1 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 0 of 6 reports. 每行为该券商近十二个月的最新研报；6 份中 0 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。